Top 20 Venture Capital Firms

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: Genetic Engineering and Biotechnology News (12/18/12)

"Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies?"

In order to start up a company, one must have capital, and for some companies, a venture capital firm may be the best source for it. Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies? Below is a list of top venture capital firms and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active "committed" capital from funds in use.

Genetic Engineering and Biotechnology News

Interim Data From TID Trial Are Positive
Source: Streetwise Reports (05/15/2025)

Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch
Source: Streetwise Reports (05/13/2025)

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential.

Biopharma Receives PDUFA Date for Lead Program
Source: Jason Kolbert (05/09/2025)

This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report.

Biopharma Shares Efficacy Data at AUA Meeting
Source: Dr. Leland Gershell (05/01/2025)

These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.

New Cell Treatment for Bladder Cancer Shows Promise
Source: Dr. Andres Maldonado (05/01/2025)

This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report.